Form 8-K - Current report:
SEC Accession No. 0001370053-24-000039
Filing Date
2024-08-05
Accepted
2024-08-05 16:18:26
Documents
15
Period of Report
2024-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K anab-20240805.htm   iXBRL 8-K 24164
2 EX-99.1 q22024earningsrelease.htm EX-99.1 103730
  Complete submission text file 0001370053-24-000039.txt   304436

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT anab-20240805.xsd EX-101.SCH 2177
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT anab-20240805_def.xml EX-101.DEF 8934
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT anab-20240805_lab.xml EX-101.LAB 30000
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT anab-20240805_pre.xml EX-101.PRE 20656
17 EXTRACTED XBRL INSTANCE DOCUMENT anab-20240805_htm.xml XML 2817
Mailing Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121
Business Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 858-362-6295
ANAPTYSBIO, INC (Filer) CIK: 0001370053 (see all company filings)

EIN.: 203828755 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37985 | Film No.: 241175012
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)